A prostate cancer diagnosis doesn't automatically mean surgery or radiation — for a large share of men, it doesn't mean immediate treatment at all. The right approach depends on your risk group, built from Gleason score / Grade Group, PSA, and clinical stage [3]. Here's what's actually on the table, mirroring how we break down BPH treatment options — every option, from lifestyle-level monitoring to surgery.
Take This Data to Your Urologist
Don't try to explain a month of symptoms in a 10-minute appointment. ManCore Pro generates a clean, professionally formatted PDF — symptom charts, supplement log, and bladder diary — ready to hand to your doctor.
Which Treatment Is Actually Right for Me? Short Answer
There's no single 'best' treatment across the board — the right choice is determined almost entirely by your risk group, not personal preference alone, though preference genuinely matters once you're choosing between options with comparable outcomes. For low-risk, Grade Group 1 disease, active surveillance is the evidence-backed default, supported directly by the ProtecT trial's finding of no significant survival difference between monitoring, surgery, and radiotherapy at 10 years — meaning treating this disease aggressively often adds side-effect risk without a corresponding survival benefit. For intermediate- and high-risk disease, surgery and radiation both have strong outcome data as roughly comparable options, with the actual choice between them typically coming down to side-effect timing preference (surgery's effects appear sooner but may resolve faster; radiation's effects develop more gradually) and individual factors like surgical candidacy. Hormone therapy enters the picture specifically for higher-risk localized disease (combined with radiation) or advanced disease, not as a universal component of every treatment plan. The practical starting point for anyone newly diagnosed: find out your specific risk group first, since that single piece of information does more to narrow the actually-relevant options than anything else.
Active Surveillance
Active surveillance means regular PSA checks, periodic MRI, and repeat biopsies — without treating the cancer unless it shows signs of progressing. It's the standard recommendation for low-risk, Grade Group 1 disease. The strongest evidence for this approach comes from the ProtecT trial, where active monitoring produced the same 10-year prostate-cancer-specific mortality as surgery and radiotherapy, despite higher rates of disease progression in the monitoring group [1]. The PIVOT trial similarly found that, among men with PSA-detected localized prostate cancer (largely lower-risk in the PSA-screening era), radical prostatectomy did not significantly reduce mortality compared with observation — though a mortality benefit did appear in men with higher PSA or higher-risk tumors [2].
- •Best fit: Grade Group 1, PSA under 10, small-volume disease, clinical stage T1-T2a
- •What it involves: PSA every 3-6 months, MRI and repeat biopsy on a set schedule (commonly annually), escalation to treatment if grade or volume progresses
- •Trade-off: avoids the side effects of surgery or radiation entirely, but requires genuine commitment to the monitoring schedule
Radical Prostatectomy
Surgical removal of the entire prostate gland, most commonly performed today as robotic-assisted laparoscopic surgery. It offers a clear pathological stage (the removed tissue is fully examined) and, for many men, is considered definitive treatment for localized disease.
- •Main side effects: erectile dysfunction (nerve-sparing technique reduces but doesn't eliminate risk — see our guide to ED after prostatectomy recovery) and urinary incontinence, both of which typically improve over 6-12 months
- •Best fit: localized disease in men healthy enough for surgery who want a single, defined treatment event with a clear pathology result
- •PSA should become essentially undetectable after successful surgery — any subsequent rise (biochemical recurrence) is closely tracked
Radiation Therapy
External beam radiotherapy (EBRT) delivers precisely targeted radiation over several weeks; brachytherapy implants radioactive seeds directly into the prostate for a more localized, shorter-course approach. Both have outcomes comparable to surgery for localized disease in trial data [1].
- •Main side effects: urinary irritation, bowel irritation, and erectile dysfunction that tends to develop more gradually than after surgery — see ED from radiation therapy
- •Best fit: men who prefer to avoid surgery, have surgical risk factors, or have disease features better suited to radiation's dosing pattern
- •PSA doesn't drop to zero after radiation (residual healthy tissue still produces some) — recovery is tracked by PSA trend rather than an absolute number
Hormone Therapy (Androgen Deprivation Therapy)
Prostate cancer cells are typically driven by testosterone. Androgen deprivation therapy (ADT) lowers testosterone or blocks its effect on cancer cells, most often used alongside radiation for higher-risk localized disease, or as primary treatment for advanced/metastatic disease. Anti-androgen medications like bicalutamide are one component of this approach.
- •Used with radiation: typically for a defined period (months to years) in intermediate- and high-risk localized disease to improve outcomes
- •Used alone: for advanced or metastatic disease, as a long-term way to control rather than cure the cancer
- •Side effects reflect low testosterone directly: hot flashes, fatigue, muscle loss, and mood changes — worth understanding through our low testosterone symptoms guide even though the cause here is treatment, not age-related decline
No single option is universally "best." The ProtecT and PIVOT trials both point to the same conclusion: for lower-risk, localized disease, aggressive treatment and careful monitoring produce similar survival, so the decision often comes down to your tolerance for treatment side effects versus the discipline of a monitoring schedule. This is a conversation to have directly with a urologist who knows your full risk profile — not a decision to make from an article alone.
Tracking Recovery, Whatever You Choose
- •Log PSA results over time rather than checking a single number in isolation — trend matters more than any one reading
- •If you have surgery or radiation, track urinary and erectile function changes monthly — most recovery happens gradually over 6-12 months
- •If you're on active surveillance, treat your monitoring schedule with the same seriousness as a treatment plan — missed follow-up is the main way surveillance fails
- •Bring a written symptom and PSA log to every appointment rather than relying on memory
Prostate Health Supplements
Super Beta Prostate Supplement
A daily formula built around beta-sitosterol and pumpkin seed oil for ongoing prostate support.
NOW Foods Pumpkin Seed Oil
Standardized cold-pressed pumpkin seed oil capsules for ongoing prostate maintenance.
Affiliate disclosure: ManCore earns a small commission on purchases made through these links at no extra cost to you.
Frequently Asked Questions
Is active surveillance safe, or am I just delaying treatment?
For appropriately selected low-risk disease (Grade Group 1, low PSA, small volume), active surveillance with a disciplined monitoring schedule has strong trial evidence behind it — the ProtecT trial found no significant difference in prostate-cancer-specific mortality at 10 years compared with immediate surgery or radiotherapy. It is not delaying treatment; it is a legitimate management strategy with defined triggers for escalating to treatment if the disease shows signs of progressing.
Which is better: surgery or radiation?
Neither is universally superior — large trial data shows broadly comparable long-term survival for localized disease. The choice usually comes down to side effect profile (surgery's side effects appear earlier and may improve faster; radiation's side effects can develop more gradually), personal preference, surgical candidacy, and specific tumor characteristics your urologist will weigh individually.
Will I need hormone therapy no matter which treatment I choose?
No. Hormone therapy is typically reserved for intermediate- to high-risk localized disease (usually combined with radiation) or advanced/metastatic disease. Low-risk, localized cancer treated with surgery or radiation alone frequently doesn't require it at all.
Can a man switch from active surveillance to treatment later if he changes his mind, even without disease progression?
Yes — active surveillance isn't a one-way commitment, and a man who becomes uncomfortable with the monitoring approach, for reasons including anxiety about living with untreated cancer even at low risk, can elect to move to treatment at any point, not only in response to a documented progression trigger.
How long does recovery typically take after radical prostatectomy before urinary and sexual function stabilize?
Most men see continued improvement over 6 to 12 months following surgery, with the most significant early gains often in the first few months and more gradual improvement continuing beyond that, which is why patience and continued engagement with recovery-focused strategies (like pelvic floor exercises) over this full window matters rather than judging results too early.
Is a second opinion from a different urologist or cancer center reasonable to seek before committing to a treatment path?
Yes, and it's a common, well-accepted practice for a diagnosis with several genuinely comparable treatment options — a second opinion, particularly from a high-volume prostate cancer center, can provide additional confidence in the recommended approach or surface an option not initially discussed, without any obligation to switch providers for ongoing care.
Does age or overall health factor into which treatment is recommended, separate from the cancer's risk group?
Yes — a man's overall health, life expectancy, and surgical candidacy meaningfully shape the treatment conversation alongside the cancer's own risk group, since the benefit of aggressive treatment for a slow-growing cancer is reduced in a man whose life expectancy from other health factors is already shorter than the time it would take that cancer to become life-threatening.
Are newer treatment approaches like focal therapy an option outside the four main categories covered here?
Some men with well-selected, localized disease may be candidates for newer, less-established focal therapy approaches (treating only the specific area of the prostate containing cancer rather than the whole gland or using systemic hormone therapy), though these remain less standardized than the four main options and are worth specifically asking about if minimizing treatment footprint is a priority.
More on Prostate Cancer
Prostate Cancer Prevention: 11 Evidence-Based Strategies
1 in 8 men will be diagnosed with prostate cancer in their lifetime. But up to 40% of cases…
Prostate Cancer Symptoms: Early Signs Every Man Should Know
Complete guide to prostate cancer symptoms — from early warning signs to advanced stage…
Prostate Cancer vs. BPH Symptoms: How to Tell the Difference and When to Worry
Both prostate cancer and BPH cause urinary problems — but the symptoms overlap almost…